# DESCRIPTION

## BACKGROUND

- introduce HER receptor family
- discuss therapeutic antibodies targeting HER2

## SUMMARY OF THE INVENTION

- describe antigen-binding constructs
- define first antigen-binding polypeptide construct
- specify framework amino acid modifications
- specify CDR amino acid modifications
- describe affinity for HER2 ECD2 antigen
- specify multiple amino acid modifications
- describe framework region modifications
- describe CDR1 modifications
- describe CDR2 modifications
- describe CDR3 modifications
- describe antigen-binding constructs with multiple modifications
- describe antigen-binding constructs with variant CDRs
- describe bivalent antigen-binding constructs

## DETAILED DESCRIPTION

- define modified 2C4 antigen-binding polypeptide constructs
- describe antigen-binding construct formats

### Antigen-Binding Constructs

- define antigen-binding construct
- describe antigen-binding construct types
- introduce antibody structure
- define hypervariable region (HVR)
- describe complementarity determining regions (CDRs)
- introduce monospecific antigen-binding construct
- describe monovalent monospecific antigen-binding construct
- describe bivalent monospecific antigen-binding construct
- introduce bispecific antigen-binding construct
- describe bispecific antigen-binding construct with two different antigens
- describe bispecific antigen-binding construct with two epitopes on same protein
- introduce biparatopic antigen-binding construct
- describe biparatopic antigen-binding construct with two epitopes on HER2
- introduce antigen-binding polypeptide constructs
- describe modified 2C4 antigen-binding polypeptide construct
- introduce parent 2C4 antibody
- describe VH and VL domains
- describe CDRs from parent 2C4 antibody
- introduce HER2 and HER2 epitopes
- describe ErbB2 and HER2 protein
- describe p185 and neu gene
- define HER receptor
- describe HER receptor structure
- introduce HER2
- describe HER2 extracellular domain
- define 2C4 epitope
- describe parent 2C4 antibodies
- introduce humanized 2C4 antibodies
- describe humanized 2C4 antibody pertuzumab
- introduce other humanized 2C4 antibodies
- describe parent 2C4 antibody characteristics
- introduce second antigen-binding polypeptide construct
- describe second antigen-binding polypeptide construct binding to HER2 ECD4
- introduce amino acid modifications
- describe amino acid modifications that increase affinity to 2C4 epitope
- define antigen-binding constructs
- describe modifications in CDR sequences
- describe modifications in framework region
- specify modifications in VH domain
- specify modifications in VL domain
- describe modifications in CDR1 of VH domain
- describe modifications in CDR2 of VH domain
- describe modifications in CDR3 of VH domain
- describe modifications in CDR1 of VL domain
- describe modifications in CDR2 of VL domain
- describe modifications in CDR3 of VL domain
- specify combinations of modifications
- describe modifications with H_S74W
- describe modifications with H_K75E
- describe modifications with H_K75W
- describe modifications with L_Y49W
- define antigen-binding constructs
- describe modified 2C4 antigen-binding polypeptide constructs
- list combinations of amino acid modifications
- describe VH and VL domains of variants
- describe CDRs in modified 2C4 antigen-binding polypeptide constructs
- describe antigen-binding constructs with modified CDRs
- describe antigen-binding constructs with specific CDR H3 modifications
- describe antigen-binding constructs with specific CDR H3 and framework region modifications
- describe antigen-binding constructs with specific VH and VL domains
- describe antigen-binding constructs with specific CDRs and framework region modifications
- introduce affinity section
- describe increased affinity for HER2 ECD2
- describe methods for determining affinity
- describe temperature conditions for determining affinity
- introduce dissociation constant and maximal binding section
- describe functional characteristics of modified 2C4 antigen-binding polypeptide constructs
- define dissociation constant
- describe ligand-protein interactions
- introduce KD measurement methods
- explain KD significance
- describe avidity
- introduce binding characteristics measurement
- explain apparent KD
- describe Bmax and B50
- introduce modified 2C4 antigen-binding polypeptide construct
- describe affinity increase embodiments
- describe thermal stability
- introduce format of antigen-binding polypeptide construct
- describe Fab format
- describe scFv format
- describe VHH format
- describe multiple modified 2C4 antigen-binding polypeptide constructs
- introduce second antigen-binding polypeptide construct
- describe Fab-Fab format
- describe scFv-scFv format
- describe Fab-scFv format
- introduce additional amino acid modifications
- describe scaffolds
- define antigen-binding construct
- describe heterodimeric Fc composition
- introduce asymmetric amino acid modifications
- provide CH3 sequence examples
- describe Fc modifications and embodiments
- discuss stability of heterodimeric Fc
- introduce methods for assessing stability
- describe purity of heterodimeric Fc formation
- introduce CH2 domain and Fc receptors
- describe FcR binding and effector functions
- discuss modifications affecting FcR binding
- provide exemplary mutations for altered FcR binding
- list antigen-binding constructs
- describe dimeric Fc with superior biophysical properties
- introduce additional modifications to improve effector function
- describe methods for producing afucosylated antigen-binding constructs
- summarize Fc modifications reducing FcγR and/or complement binding
- describe linkers and linker polypeptides
- introduce antigen-binding constructs with two antigen-binding polypeptide constructs
- describe linker polypeptides capable of forming a complex or interface
- introduce alternate scaffolds for linker polypeptides

### Testing of Antigen-Binding Constructs: HER2 Binding

- test antigen-binding constructs in vitro and/or in vivo
- describe in vitro assays for therapeutic or prophylactic utility
- motivate use of cancer cell lines expressing HER2
- describe assays for identifying suitable antigen-binding constructs
- summarize methods for measuring cell viability and cytotoxicity
- describe assays for selecting antigen-binding constructs inducing cell death
- motivate use of antigen-binding assays and cell binding assays
- describe methods for determining binding characteristics
- summarize in vivo assays for testing antigen-binding constructs

### Reference Antigen-Binding Construct

- define reference antigen-binding constructs for comparison

### Antigen-Binding Constructs and Antibody Drug Conjugates (ADC)

- introduce ADCs
- describe methods of preparing ADCs
- motivate maytansine drug moieties
- describe auristatins
- motivate chemotherapeutic agents
- describe conjugate linkers
- motivate cleavable linkers
- describe non-cleavable linkers
- summarize preparation of ADCs
- describe specific examples of ADC preparation methods
- provide references to prior art

### Methods of Preparation of Antigen-Binding Constructs

- introduce recombinant methods
- provide isolated nucleic acid encoding antigen-binding construct
- describe vectors comprising nucleic acid
- provide host cell comprising nucleic acid
- define "substantially purified"
- describe recombinant production in bacteria
- describe expression of antigen-binding construct fragments in bacteria
- describe expression in eukaryotic microbes
- describe expression in multicellular organisms
- describe plant cell cultures as hosts
- describe vertebrate cells as hosts
- describe production in stable mammalian cells
- describe glycosylation of antigen-binding constructs
- describe aglycosylation of antigen-binding constructs
- describe deglycosylation of antigen-binding constructs
- describe purification of antigen-binding constructs
- describe identification of desired glycosylated antigen-binding construct
- describe chemical synthesis of antigen-binding constructs
- describe post-translational modifications of antigen-binding constructs
- describe attachment of labels to antigen-binding constructs

### Pharmaceutical Compositions

- introduce pharmaceutical compositions comprising antigen-binding construct
- describe pharmaceutically acceptable carriers
- describe formulation of compositions for administration

### Methods of Treatment

- define disorder
- define subject
- define mammal
- define treatment
- describe desirable effects of treatment
- define effective amount
- describe administration methods
- describe delivery systems
- describe local administration
- describe controlled release systems
- describe nucleic acid administration
- describe combination therapy
- describe administration with other treatments
- describe human antigen-binding constructs
- describe methods of treating cancers
- describe methods of treating HER2+ cancers

### Kits and Articles of Manufacture

- describe kits comprising antigen-binding constructs
- outline components of kit
- describe containers for kit components
- specify types of containers
- describe instruments for assisting with administration
- outline types of instruments
- describe article of manufacture
- outline components of article of manufacture
- describe container and label or package insert
- specify types of containers
- describe composition in container
- outline active agents in composition
- describe label or package insert
- outline information on label or package insert
- describe multiple containers in article of manufacture
- outline components of multiple containers
- describe package insert indicating use
- outline additional materials in article of manufacture
- describe buffers and diluents
- outline other materials desirable from commercial and user standpoint
- describe polypeptides and polynucleotides
- define isolated
- describe polypeptide and peptide
- outline amino acid analogs and mimetics
- describe nucleic acid and polynucleotide

## EXAMPLES

- introduce examples of specific embodiments for making and using the antigen-binding construct described herein

### Example 1: Affinity-Improved Anti-HER2 Antibodies Based on Pertuzumab

- engineer variable region of pertuzumab to identify mutations that increase affinity for HER2
- prepare engineered antibodies in two formats: monovalent, one-armed (OA) and bivalent, mono-specific, full-sized antibody (FSA
- describe mutations in variable region of heavy and/or light chains of pertuzumab

### Example 2: Preparation of Variant Antigen-Binding Constructs with Improved Affinity for HER2

- clone and express genes encoding antibody heavy and light chains
- express and purify antigen-binding constructs in CHO cells
- analyze heterodimer purity and further purify by size exclusion chromatography (SEC)

### Example 3: Affinity of Variant Antigen-Binding Constructs as Measured by Surface Plasmon Resonance

- measure affinity of variant antigen-binding constructs for HER2 using surface plasmon resonance (SPR)
- determine association constant and equilibrium dissociation constant
- compare affinity of variant antigen-binding constructs to wild-type pertuzumab

### Example 4: Measurement of Thermal Stability of Variant Antigen-Binding Constructs by Differential Scanning Calorimetry

- determine thermal stability of Fabs of antigen-binding constructs using differential scanning calorimetry (DSC)
- compare thermal stability of variant antigen-binding constructs to wild-type pertuzumab

### Example 5: Measurement of Binding Affinity of a Variant Antigen-Binding Construct in FSA Format to Whole Cells by Flow Cytometry

- measure binding affinity of variant antigen-binding construct in FSA format to cells expressing varying levels of HER2
- compare binding affinity to wild-type pertuzumab in FSA format

### Example 6: Ability of a Variant Antigen-Binding Construct in FSA Format to Inhibit Cell Growth

- examine ability of variant antigen-binding construct in FSA format to inhibit growth of cancer cell lines expressing varying levels of HER2
- compare growth inhibitory activity to wild-type pertuzumab in FSA format

### Example 7: Assessment of Affinity of Literature Pertuzumab Variants for HER2 by SPR

- prepare literature pertuzumab variants and assess affinity for HER2 using SPR
- compare affinity measurements to function ratios reported in literature

### Example 8: Design and Preparation of Combination Variant Antigen-Binding Constructs Based on Selected 1X Amino Acid Substitution Variants, and Measurement of Affinity for ECD2 of HER2 by SPR

- identify variant antigen-binding constructs with increased affinity
- measure affinity by SPR and thermal stability by DSC

### Example 9: Measurement of Thermal Stability of Selected Combination Variant Antigen-Binding Constructs by Differential Scanning Calorimetry (DSC)

- assess thermal stability of Fab region by DSC
- determine Tm values of Fab region
- compare Tm values to WT pertuzumab
- identify variants with Tm values within 10° C. of WT
- identify variants with Tm values within 5° C. of WT
- determine if variants are amenable to large scale manufacturing
- express variants in FSA format
- test binding of variants to cells expressing HER2
- measure Bmax and B50 values
- compare Bmax and B50 values to WT pertuzumab
- determine if variants are capable of binding to HER2
- test growth inhibition of variants
- compare growth inhibition of variants to WT pertuzumab
- determine if variants have enhanced efficacy

